The FDA grants Fast Track designation to nipocalimab for SLE, following positive results from the phase 2b JASMINE trial.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (obinutuzumab) in adults with systemic lupus ...

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Please provide your email address to receive an email when new articles are posted on . SLE-DAS remission and low disease activity discriminated between patients taking active drug vs. placebo. Both ...

Phase III results put obinutuzumab in line for approval ...

WASHINGTON — The investigational anti-CD40 ligand agent dapirolizumab pegol (DZP) outperformed placebo in improving disease activity and reducing high-dose corticosteroid use in patients with systemic ...

For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process. In ...

Differences in socioeconomic status and economic stability can disproportionately affect racial/ethnic groups that have been marginalized. These effects can be even more compounded for people who live ...

Autoimmune disease hair loss can happen with alopecia areata, lupus, thyroid diseases, rheumatoid arthritis, Crohn’s disease, and scalp psoriasis. Each disease has different effects, ...

About Gazyva/Gazyvaro Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death, and a glycoengineered Fc region, for higher ...